l-asparaginase + daunorubicin + cytarabine + fludarabine + etoposide

This is an **intensive combination chemotherapy regimen** comprised of five antineoplastic agents: l-asparaginase, daunorubicin, cytarabine, fludarabine, and etoposide. Each drug has a distinct mechanism of action targeting acute myeloid leukemia (AML) and other acute leukemias. - **l-asparaginase**: An enzyme that hydrolyzes asparagine, depriving leukemic cells (especially lymphoblasts) of an essential amino acid for protein synthesis, leading to cell death[1][3][13]. - **daunorubicin**: An anthracycline that intercalates DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis[1][3][5]. - **cytarabine**: A cytosine nucleoside analog that inhibits DNA synthesis, mainly during the S phase, resulting in cell cycle arrest and apoptosis[1][3][5]. - **fludarabine**: A purine nucleoside analog which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, blocking DNA synthesis and repair[2][12]. - **etoposide**: A topoisomerase II inhibitor, causing DNA strand breaks and preventing cell division[2][12]. This multi-agent regimen is used in the induction and consolidation phases of therapy for high-risk or relapsed acute myeloid leukemia in adults, leveraging complementary mechanisms to maximize cytotoxicity and reduce the risk of resistance[1][2][3][12].